ACADIA Pharmaceuticals (ACAD) vs Arcus Biosciences (RCUS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Arcus Biosciences (RCUS) has outperformed ACADIA Pharmaceuticals (ACAD) over the past year, gaining 74.8% versus a loss of 8.8%. Over five years, ACAD leads with a +12.2% price change compared with -28.7% for RCUS. ACADIA Pharmaceuticals is the larger company by market cap ($3.39 billion vs $3.08 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACAD | RCUS |
|---|---|---|
| Share price | $19.65 | $24.52 |
| Market cap | $3.39B | $3.08B |
| 1-day change | -0.46% | +0.99% |
| YTD return | -26.43% | +2.90% |
| 1-year return | -8.77% | +74.77% |
| 5-year return | +12.22% | -28.70% |
| P/E ratio (TTM) | 8.81 | — |
| Forward P/E | 22.12 | — |
| EPS (TTM) | $2.23 | $-3.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $30.96 | $31.74 |
| 52-week low | $19.46 | $14.26 |
| Distance from 52-week high | -36.53% | -22.74% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +63.66% | +62.77% |
| Average volume | 1.84M | 1.32M |
| Shares outstanding | 172.31M | 125.77M |
| Employees | 796 | 601 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RCUS has outperformed ACAD by 83.5 percentage points over the past year.
About ACADIA Pharmaceuticals
ACAD stock →ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Health Care · Biotechnology: Pharmaceutical Preparations · 796 employees
About Arcus Biosciences
RCUS stock →Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees
ACAD vs RCUS FAQ
Which is bigger, ACADIA Pharmaceuticals or Arcus Biosciences?
ACADIA Pharmaceuticals (ACAD) is larger, with a market capitalization of $3.39B compared with $3.08B for Arcus Biosciences (RCUS).
Which stock has performed better over the past year, ACAD or RCUS?
RCUS returned +74.77% over the past 12 months, compared with -8.77% for ACAD (price return, excluding dividends). Past performance does not predict future results.
Are ACADIA Pharmaceuticals and Arcus Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.